crizotinib ALK Expression, +19 more biomarkers Systemic Anaplastic Large Cell Lymphoma Relapse/refractory crizotinib targeted therapy
alectinib ALK Fusion Non-Small Cell Lung Carcinoma Advanced, +1 more state Subsequent line alectinib targeted therapy
alectinib ALK Expression, +19 more biomarkers Systemic Anaplastic Large Cell Lymphoma Subsequent line alectinib targeted therapy
alectinib ALK Fusion Non-Small Cell Lung Carcinoma Advanced, +1 more state First line alectinib targeted therapy
brigatinib ALK Fusion Non-Small Cell Lung Carcinoma Advanced, +1 more state First line brigatinib targeted therapy
brigatinib ALK Fusion Non-Small Cell Lung Carcinoma Advanced, +1 more state Subsequent line brigatinib targeted therapy